Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: Results from an open-label, randomized Trial Academic Article uri icon

Overview

MeSH Major

  • Cyclosporine
  • Graft Rejection
  • Immunosuppressive Agents
  • Kidney Transplantation
  • Sirolimus
  • Tacrolimus

abstract

  • This study demonstrated that SRL-based therapy was efficacious in high-risk renal allograft recipients in the first year after transplant, providing equivalent efficacy with CsA or TAC, similar graft survival, low biopsy-confirmed acute rejection rates, excellent renal function, and an acceptable safety profile.

publication date

  • November 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/TP.0b013e318187bab0

PubMed ID

  • 19005398

Additional Document Info

start page

  • 1187

end page

  • 95

volume

  • 86

number

  • 9